ANI Pharmaceuticals ANIP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $109.22M+6.0% | $103.49M+23.7% | $98.69M+19.3% | $94.21M+19.5% | $103.04M+37.7% | |
| Rare Disease and Brands | $128.24M+36.3% | $143.57M+34.3% | $129.13M+96.8% | $117.16M+97.8% | $94.08M+50.3% | |
| Other (expense)income , net by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Generics and Other | $40.32M-16.9% | $33.19M+36.1% | $35.08M+7.5% | $38.18M+27.1% | $48.54M+67.5% | |
| Rare Disease and Brands | $36.25M+71.5% | $48.99M+71.1% | $41.66M+668% | $29.46M+92.3% | $21.13M-8.5% | |
| Operating Income (Loss) by Business | ||||||
| Generics and Other | $40.32M-16.9% | $33.19M+36.1% | $35.08M+7.5% | $38.18M+27.1% | $48.54M+67.5% | |
| Rare Disease and Brands | $36.25M+71.5% | $48.99M+71.1% | $41.66M+668% | $29.46M+92.3% | $21.13M-8.5% | |
| Net Interest Expense by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Cost of sales (excluding depreciation and amortization) by Business | ||||||
| Generics and Other | $59.59M+28.2% | $58.49M+24.5% | $53.74M+26.2% | $43.23M+2.9% | $46.5M+26.4% | |
| Rare Disease and Brands | $33.99M+28.1% | $41.78M+25.4% | $39.65M+93.5% | $31.38M+100% | $26.54M+115% | |
| Selling, General and Administrative Expense by Business | ||||||
| Generics and Other | $1.52M+8.1% | $1.47M+6.5% | $1.41M+1.5% | $1.39M+3.3% | $1.41M+39.4% | |
| Rare Disease and Brands | $55.19M+30.0% | $50.88M+29.6% | $43.98M+23.2% | $51.19M+94.3% | $42.44M+72.0% | |
| Unrealized gain (loss) on investment in equity securities by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Research and Development expense by Business | ||||||
| Generics and Other | $7.79M+18.2% | $10.34M-5.6% | $8.47M+38.4% | $11.41M+110% | $6.59M-17.8% | |
| Rare Disease and Brands | $2.81M-29.3% | $1.92M-66.3% | $3.83M-4.3% | $5.12M+174% | $3.98M+59.6% | |
| D&A by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Contingent consideration fair value adjustment by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Net Revenues by Product | ||||||
| Brand royalties and other revenues | $21.54M— | —— | —— | —— | $0— | |
| Brands | $12.33M-50.9% | $12.32M-37.9% | $10.68M+16.1% | $13.2M+31.6% | $25.12M-2.2% | |
| Cortrophin Gel | $75.12M+42.1% | $111.43M+87.6% | $101.85M+93.8% | $81.65M+66.0% | $52.85M+43.1% | |
| Generic pharmaceutical products | $105.4M+6.8% | $100.76M+28.2% | $94.38M+20.6% | $90.3M+22.1% | $98.68M+40.5% | |
| ILUVIEN and YUTIQ | $19.26M+19.5% | $19.84M-28.2% | $16.6M+329% | $22.32M— | $16.11M— | |
| Other generic revenues | $3.82M-12.5% | —— | —— | —— | $4.36M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.